Current treatment options for pancreatic carcinoma (Q37864970)

24 August 2017

1 reference

title

Current treatment options for pancreatic carcinoma (English)

1 reference

24 August 2017

Emily Castellanos

1

1 reference

24 August 2017

Jordan Berlin

series ordinal

2

1 reference

24 August 2017

Dana Backlund Cardin

series ordinal

3

1 reference

24 August 2017

publication date

1 June 2011

1 reference

24 August 2017

published in

Current Oncology Reports

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

195-205

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-011-0164-1

24 August 2017

exact match

0 references

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Specific Antigen in Serum of Patients with Colon Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Role of tumour markers, cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Pancreatic cancer: epidemiology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Locally advanced pancreatic cancer: current therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0164-1

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

12 December 2020

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

12 December 2020

Borderline resectable pancreatic cancer: on the edge of survival

1 reference

12 December 2020

Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study

1 reference

12 December 2020

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

1 reference

12 December 2020

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

12 December 2020

Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer

1 reference

12 December 2020

Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer

1 reference

12 December 2020

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas

1 reference

12 December 2020

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.

1 reference

12 December 2020

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study

1 reference

12 December 2020

A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.

1 reference

12 December 2020

Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma

1 reference

12 December 2020

Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group

1 reference

12 December 2020

Preoperative Evaluation of Pancreatic Masses with Positron Emission Tomography Using 18F-fluorodeoxyglucose: Diagnostic Limitations

1 reference

12 December 2020

Alternate paclitaxel-gemcitabine and paclitaxel-vinorelbine biweekly administration in non-small cell lung cancer patients: a phase II study.

1 reference

12 December 2020

Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study

1 reference

12 December 2020

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

12 December 2020

Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

10.1007/S11912-011-0164-1

Identifiers

DOI

1 reference

24 August 2017

1 reference